跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 541 条关于
“CCNE1 amplification”
全部
541
临床试验
293
药物
5
机构
1
资讯
242
去年
FDA Grants Fast Track Designation to Incyclix Bio's INX-315 for CCNE1-Amplified Platinum-Resistant Ovarian Cancer
去年
Repare Therapeutics to Present Phase 1 MYTHIC Trial Data of Lunresertib and Camonsertib Combination in Advanced Cancers
去年
Repare Therapeutics Advances Oncology Pipeline with Promising Clinical Data
去年
Molecular Testing Advances Personalized Treatment Strategies in Ovarian Cancer
去年
Phase IIb ADAGIO Trial: Adavosertib Shows Limited Efficacy with High Toxicity in Uterine Serous Carcinoma
去年
Adavosertib Shows Promise in Uterine Serous Carcinoma Despite Tolerability Challenges
5个月前
Debiopharm Reports First Clinical Data from MYTHIC Trial Combining WEE1 and PKMYT1 Inhibitors at AACR 2026
5个月前
Incyclix Bio Secures $5M Series B Extension to Advance CDK2 Inhibitor INX-315 in Resistant Breast and Ovarian Cancers
2年前
Repare Therapeutics Advances Oncology Pipeline with Multiple Clinical Trials
去年
Dual SHP2 and FGFR2 Inhibition Shows Promise in Treatment-Resistant Gastric Cancer
第 1 页,共 25 页
上一页
下一页